Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial

被引:1
|
作者
Lankarani, Kamran Bagheri [1 ]
Safa, Hoda [2 ,4 ]
Ghahramani, Sulmaz [1 ]
Sayari, Mohammad [1 ]
Malekhosseini, Seyed-Ali [3 ]
机构
[1] Shiraz Univ Med Sci, Inst Hlth, Hlth Policy Res Ctr, Shiraz, Iran
[2] Shiraz Univ Med Sci, Dept Gastroenterol, Shiraz, Iran
[3] Shiraz Univ Sci, Shiraz Transplant Res Ctr, Shiraz, Iran
[4] Hormozgan Univ Med Sci, Dept Gastroenterol, Bandar Abbas, Iran
关键词
Acute kidney injury; Early allograft dysfunction; Length of hospital stay; Nosocomial infection; Somatostatin analog; EARLY ALLOGRAFT DYSFUNCTION; ISCHEMIA-REPERFUSION INJURY; RENAL-FUNCTION; HYPERTENSION; DEFINITION; VALIDATION; BAICALIN;
D O I
10.6002/ect.2022.0080
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Objectives: Acute kidney injury and early allograft dysfunction are 2 common complications after liver transplant. Octreotide, through its various mechanisms, may have a role in preventing these complications.Materials and Methods: In this randomized, double-blind placebo-controlled clinical trial, we randomly assigned 50 patients who underwent deceased donor liver transplant and fulfilled the study inclusion requirements to receive either octreotide infusion for 3 days in the first 3 days after transplant in the intensive care unit or placebo. The eligible patients were properly informed while on the transplant wait list and gave their consent to participate in the study. The rates of acute kidney injury within the first 7 days after transplant (based on KDIGO criteria), early allograft dysfunction, and nosocomial infection; total length of hospital stays and intensive care unit admissions; and intubation time were recorded and compared between the 2 groups.Results: No significant differences were found between the 2 groups with regard to demographic charac-teristics and graft factors (P > .05). However, acute kidney injury, early allograft dysfunction, and nosocomial infection rates were significantly lower in the octreotide group compared with the control group (P < .05). Moreover, a significant difference was observed between the 2 groups with regard to length of hospital stay and intensive care unit admissions (P < .05). For infection, female patients had a higher likelihood of infection than male patients (odds ratio = 23.19). Intensive care unit admission was associated with a higher probability of early graft dysfunction (odds ratio = 1.34). In contrast, longer intubation time was associated with a decrease in the probability of early graft dysfunction (odds ratio = 0.93).Conclusions: This study showed that octreotide infusion in the first 3 days after liver transplant could improve renal and allograft function and reduce infection and length of hospital stay.
引用
收藏
页码:835 / 841
页数:7
相关论文
共 50 条
  • [1] Double-blind placebo-controlled randomized trial of N-acetylcysteine infusion following live donor liver transplantation
    Thirunavayakalathil, Mohammed Abdullatheef
    Varghese, Christi Titus
    Bharathan, Viju Kumar
    Chandran, Biju
    Nair, Krishnanunni
    Mallick, Shweta
    Mathew, Johns Shaji
    Amma, Binoj Sivasankara Pillai Thankamony
    Menon, Ramachandran Narayana
    Gopalakrishnan, Unnikrishnan
    Balakrishnan, Dinesh
    Sudheer, Othiyil Vayoth
    Surendran, Sudhindran
    HEPATOLOGY INTERNATIONAL, 2020, 14 (06) : 1075 - 1082
  • [2] Protocol for a prospective double-blind, randomised, placebo-controlled feasibility trial of octreotide infusion during liver transplantation
    Fabes, Jeremy
    Ambler, Gareth
    Shah, Bina
    Williams, Norman R.
    Martin, Daniel
    Davidson, Brian R.
    Spiro, Michael
    BMJ OPEN, 2021, 11 (12):
  • [3] The Effect of Octreotide on Urine Output During Orthotopic Liver Transplantation and Early Postoperative Renal Function; A Randomized, Double-Blind, Placebo-Controlled Trial
    Sahmeddini, Mohammad Ali
    Amini, Afshin
    Naderi, Nima
    HEPATITIS MONTHLY, 2013, 13 (09)
  • [4] Double-blind placebo-controlled randomized trial of N-acetylcysteine infusion following live donor liver transplantation
    Mohammed Abdullatheef Thirunavayakalathil
    Christi Titus Varghese
    Viju Kumar Bharathan
    Biju Chandran
    Krishnanunni Nair
    Shweta Mallick
    Johns Shaji Mathew
    Binoj Sivasankara Pillai Thankamony Amma
    Ramachandran Narayana Menon
    Unnikrishnan Gopalakrishnan
    Dinesh Balakrishnan
    Othiyil Vayoth Sudheer
    Sudhindran Surendran
    Hepatology International, 2020, 14 : 1075 - 1082
  • [5] Creatine Supplementation in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial
    Alves, Christiano R. R.
    Santiago, Bianca M.
    Lima, Fernanda R.
    Otaduy, Maria C. G.
    Calich, Ana Luisa
    Tritto, Aline C. C.
    de Sa Pinto, Ana Lucia
    Roschel, Hamilton
    Leite, Claudia C.
    Benatti, Fabiana B.
    Bonfa, Eloisa
    Gualano, Bruno
    ARTHRITIS CARE & RESEARCH, 2013, 65 (09) : 1449 - 1459
  • [6] Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial
    Sattarinezhad, A.
    Roozbeh, J.
    Yeganeh, B. Shirazi
    Omrani, G. R.
    Shams, M.
    DIABETES & METABOLISM, 2019, 45 (01) : 53 - 59
  • [7] Pregabalin and pain after total knee arthroplasty: a double-blind, randomized, placebo-controlled, multidose trial
    YaDeau, J. T.
    Lin, Y.
    Mayman, D. J.
    Goytizolo, E. A.
    Alexiades, M. M.
    Padgett, D. E.
    Kahn, R. L.
    Jules-Elysee, K. M.
    Ranawat, A. S.
    Bhagat, D. D.
    Fields, K. G.
    Goon, A. K.
    Curren, J.
    Westrich, G. H.
    BRITISH JOURNAL OF ANAESTHESIA, 2015, 115 (02) : 285 - 293
  • [8] Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial
    Bokoch, Michael P.
    Tran, Amy T.
    Brinson, Erika L.
    Marcus, Sivan G.
    Reddy, Meghana
    Sun, Elizabeth
    Roll, Garrett R.
    Pardo, Manuel
    Fields, Scott
    Adelmann, Dieter
    Kothari, Rishi P.
    Legrand, Matthieu
    BMJ OPEN, 2023, 13 (11):
  • [9] Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial
    Mooney, M. E.
    Schmitz, J. M.
    Allen, S.
    Grabowski, J.
    Pentel, P.
    Oliver, A.
    Hatsukami, D. K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (04) : 344 - 352
  • [10] Perioperative prostaglandin e1 infusion in living donor liver transplantation: A double-blind, placebo-controlled randomized trial
    Bharathan, Viju Kumar
    Chandran, Biju
    Gopalakrishnan, Unnikrishnan
    Varghese, Christi Titus
    Menon, Ramachandran N.
    Balakrishnan, Dinesh
    Sudheer, O. V.
    Dhar, Puneet
    Surendran, Sudhindran
    LIVER TRANSPLANTATION, 2016, 22 (08) : 1067 - 1074